ASH 2022 | Abbv-319: a novel, CD19-GRM antibody-drug conjugate being explored for R/R B-cell malignancies
John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, briefly discusses the mechanism of action of Abbv-319, a novel CD19-GRM antibody-drug conjugate (ADC), being evaluated in a Phase I trial for patients with relapsed/refractory (R/R) B-cell malignancies (NCT05512390). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Merck: Consultancy, Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria; Medison Ventures: Consultancy; Antengene: Consultancy; Novartis: Honoraria; Janssen: Honoraria; Amgen: Honoraria; Astra Zeneca: Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria, Other: DSMB; Gilead: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Inctye: Honoraria; Pfizer: Honoraria; Lymphoma Canada: Membership on an entity’s Board of Directors or advisory committees.
